Tag: nasdaq:agio
November 13, 2019
Agios Pharmaceuticals Closes Public Offering
The company has additionally announced the option for its underwriters to purchase an additional 1.23 million shares at US$31 each.
January 1, 2019
An Investor’s Guide to Clinical Trials
Clinical trials can be one of the more challenging US Food and Drug Administration processes to understand, but grasping the... December 3, 2018
Agios Presents Updated Data from the Ivosidenib Phase 1 Dose-Escalation and Expansion Trial
Agios Pharmaceuticals (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today presented... November 16, 2018
Agios Presents Updated Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma
Agios Pharmaceuticals (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today presented...
October 2, 2018
3 Top Biotech Stocks on the TSX Year-to-Date
Which biotech stocks on the TSX have performed the best year-to-date? These three companies have risen to the top of... July 20, 2018
FDA Grants Approval of Agios’ Pharmaceuticals’ TIBSOVO®
Agios Pharmaceuticals (NASDAQ:AGIO) has announced that TIBSOVO was granted approval from the US Food and Drug Administration (FDA) for treatment... June 26, 2018